Health
Novo Nordisk's Wegovy® HD available now nationwide
Wegovy® HD (semaglutide) injection 7.2 mg is available now nationwide, delivering the highest weight loss of any Wegovy® injection to date.2 This advancement builds on the many offerings for patients within the Wegovy® label and opens up a new option for American adults living with obesity looking to lose weight and keep it off, along with diet and exercise.2
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"Wegovy® HD available through 70,000+ US pharmacies, NovoCare® Pharmacy, select telehealth providers, and more","length":114,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":114,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"STEP UP trial data showed average weight loss of ~21% with Wegovy® HD at 72 weeks in adults with obesity if all patients stayed on treatment* and ~19% regardless of whether patients stayed on treatment**1","length":204,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":204,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Wegovy® HD further expands the offerings for patients within the Wegovy® label, inclusive of multiple formulations, including Wegovy® pill, and indications not available with other GLP-1 weight loss medicines","length":223,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":223,"olType":false},{"type":"text","content":"PLAINSBORO, N.J., April 7, 2026 /PRNewswire/ -- Wegovy® HD (semaglutide) injection 7.2 mg is available now nationwide, delivering the highest weight loss of any Wegovy® injection to date.2 This advancement builds on the many offerings for patients within the Wegovy® label and opens up a new option for American adults living with obesity looking to lose weight and keep it off, along with diet and exercise.2","length":409,"tagName":"p"},{"type":"text","content":""We know that patients are looking for additional options for weight loss, and with Wegovy® HD we are answering that call. Whether patients haven't yet reached their weight loss goals on lower-dose Wegovy® injectables, or they simply have a more significant amount of weight to lose, the 21% weight loss demonstrated in the STEP UP trial, if all patients stayed on treatment, shows what's possible with this new dose, and that's an opportunity we're excited to provide," said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk. "Additionally, Wegovy® is the only weight loss medicine for adults with obesity proven to reduce the risk of events such as stroke, heart attack, or cardiovascular death in those who also have known heart disease. Each dose of Wegovy®, including Wegovy® HD, will be available nationwide through the chan...